Ara
Toplam kayıt 12, listelenen: 1-10
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
(Elsevier Inc., 2022)
Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib ...
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
(Sage Publications Ltd, 2020)
Introduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with ...
COVID-19 clinical course and blood groups: Turkish population-based study
(Tubitak Scientific & Technical Research Council Turkey, 2021)
Background/aim: SARS-CoV-2 enters the cell through the binding of the S glycoprotein on the surface of the virus to the angiotensin-converting enzyme 2 (ACE-2) in the host cells and also SARS-CoV S protein binding to ACE-2 ...
Convalescent plasma therapy in patients with COVID-19
(Pergamon-Elsevier Science Ltd, 2021)
Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ...
Tyrosine kinase inhibitors and COVID-19
(Sage Publications Ltd, 2020)
[No Abstract Available]
Convalescent plasma therapy in patients with COVID-19 (Letter)
(Pergamon-Elsevier Science Ltd, 2021)
[No Abstract Available]
Convalescent plasma therapy in patients with COVID-19
(Wiley, 2020)
There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
(Springer-Verlag Italia Srl, 2022)
Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course ...
The outcome of COVID-19 in patients with hematological malignancy
(Wiley, 2021)
In this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 ...
The outcome of COVID-19 in patients with hematological malignancy (Letter)
(Wiley, 2021)
[No Abstract Available]